Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals

(2020) Alba Grifoni et al.   CELL

The Challenges of Vaccine Development against a New Virus during a Pandemic

(2020) Michael S. Diamond et al.   Cell Host & Microbe

Balancing Expediency and Scientific Rigor in Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Development

(2020) Kevin W Graepel et al.   JOURNAL OF INFECTIOUS DISEASES

Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial

(2020) Feng-Cai Zhu et al.   LANCET

Rapid COVID-19 vaccine development

(2020) Barney S. Graham   SCIENCE

Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus

(2020) Bette Korber et al.   CELL

Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes

(2020) Shengli Xia et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial

(2020) Feng-Cai Zhu et al.   LANCET

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

(2020) Pedro M Folegatti et al.   LANCET

Phase 1/2 study of COVID-19 RNA vaccine BNT162b1 in adults

(2020) Mark J. Mulligan et al.   NATURE

A perspective on potential antibody-dependent enhancement of SARS-CoV-2

(2020) Ann M. Arvin et al.   NATURE

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

(2020) Lisa A. Jackson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome

(2020) Daniela Weiskopf et al.   Science Immunology

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial

(2020) Shengli Xia et al.   LANCET INFECTIOUS DISEASES

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

(2020) Edward E. Walsh et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults

(2020) Evan J. Anderson et al.   NEW ENGLAND JOURNAL OF MEDICINE

A randomized, open-labelled, non-inferiority phase 4 clinical trial to evaluate the immunogenicity and safety of the live, attenuated, oral rotavirus vaccine, ROTAVAC® in comparison with a licensed rotavirus vaccine in healthy infants

(2019) Raches Ella et al.   VACCINE

Persistence of Immune Responses With an Inactivated Japanese Encephalitis Single-Dose Vaccine, JENVAC and Interchangeability With a Live-Attenuated Vaccine

(2019) Krishna Mohan Vadrevu et al.   JOURNAL OF INFECTIOUS DISEASES

A Phase 4, multicentre, randomized, single-blind clinical trial to evaluate the immunogenicity of the live, attenuated, oral rotavirus vaccine (116E), ROTAVAC®, administered simultaneously with or without the buffering agent in healthy infants in India

(2018) Raches Ella et al.   Human Vaccines & Immunotherapeutics

Advances in aluminum hydroxide-based adjuvant research and its mechanism

(2015) Peng He et al.   Human Vaccines & Immunotherapeutics

Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian children in the second year of life

(2014) Nita Bhandari et al.   VACCINE

Imidazoquinoline Toll-like receptor 8 agonists activate human newborn monocytes and dendritic cells through adenosine-refractory and caspase-1–dependent pathways

(2012) Victoria J. Philbin et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Potent Adjuvanticity of a Pure TLR7-Agonistic Imidazoquinoline Dendrimer

(2012) Nikunj M. Shukla et al.   PLoS One

Superior Immunogenicity of Inactivated Whole Virus H5N1 Influenza Vaccine is Primarily Controlled by Toll-like Receptor Signalling

(2011) Felix Geeraedts et al.   PLoS Pathogens

Immunogenicity and safety study of Indirab: A Vero cell based chromatographically purified human rabies vaccine

(2010) Gadey Sampath et al.   VACCINE

Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease

(2008) Maria Florencia Delgado et al.   NATURE MEDICINE